Interestingly, we found that both BRAFi and dual therapy significantly increased CD8+ T‐cell tumor infiltration, while anti‐mVEGFA monotherapy did not influence their recruitment (Fig. 4A). The gene discussed is CD8A; the disease is neoplasm.